Patient engagement in pharmaceutical development: Where are we? - Report from a symposium
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Patient engagement in pharmaceutical development : Where are we? - Report from a symposium. / Stegemann, Sven; Birna Almarsdóttir, Anna; Vermehren, Charlotte.
I: European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, Bind 185, 2023, s. 1-4.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Patient engagement in pharmaceutical development
T2 - Where are we? - Report from a symposium
AU - Stegemann, Sven
AU - Birna Almarsdóttir, Anna
AU - Vermehren, Charlotte
N1 - Copyright © 2023 Elsevier B.V. All rights reserved.
PY - 2023
Y1 - 2023
N2 - In recent years, the term "patient engagement" has found its way into healthcare and specifically into the field of drug development. To better understand the actual status of "patient engagement" in drug development, a symposium was organized by the Drug Research Academy of the University of Copenhagen (Denmark) on November 16, 2022. The symposium brought together experts from regulatory authorities, industry, academia and patients to share their views and experience of and with patient engagement in drug product development. The symposium led to intensive discussions among the speakers and the audience, confirming that viewpoints and experiences of the different stakeholder provide important input into the promoting patient engagement along the entire drug development life cycle.
AB - In recent years, the term "patient engagement" has found its way into healthcare and specifically into the field of drug development. To better understand the actual status of "patient engagement" in drug development, a symposium was organized by the Drug Research Academy of the University of Copenhagen (Denmark) on November 16, 2022. The symposium brought together experts from regulatory authorities, industry, academia and patients to share their views and experience of and with patient engagement in drug product development. The symposium led to intensive discussions among the speakers and the audience, confirming that viewpoints and experiences of the different stakeholder provide important input into the promoting patient engagement along the entire drug development life cycle.
U2 - 10.1016/j.ejpb.2023.02.005
DO - 10.1016/j.ejpb.2023.02.005
M3 - Journal article
C2 - 36801478
VL - 185
SP - 1
EP - 4
JO - European Journal of Pharmaceutics and Biopharmaceutics
JF - European Journal of Pharmaceutics and Biopharmaceutics
SN - 0939-6411
ER -
ID: 336817614